Skip to main content
NERV logo

NERV · Minerva Neurosciences, Inc. · Investor Relations

Track NERV — free
$3.44 +0.12 (+3.61%)
Market Cap
$162.34M
Shares
47.75M
Volume · Oct 6 60.99K Avg daily vol (3M) 187.53K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-09-09 2026 Cantor Global Healthcare Conference Conference
2026-09-08 Wells Fargo Healthcare Conference Conference
2026-06-04 2026 Jefferies Global Healthcare Conference Conference
2026-03-18 Stifel 2026 Virtual CNS Forum Webcast
2026-03-10 Citizens Life Sciences Conference Conference
2026-02-03 Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality Event
2023-09-27 Annual Shareholder Meeting Shareholder meeting
2023-05-15 Minerva Neurosciences First Quarter 2023 Conference Call Earnings call
2023-03-08 Minerva Neurosciences FY 2022 Financial Results and Business Updates Event
2022-11-09 Minerva Neurosciences Third Quarter 2022 Conference Call Earnings call
2022-04-13 Minerva Neurosciences Roluperidone Update Event
2021-11-08 Minerva Neurosciences Third Quarter 2021 Conference Call Earnings call
2021-08-02 Minerva Neurosciences Second Quarter 2021 Conference Call Earnings call
2021-06-16 JMP Securities Life Sciences Conference Conference
2021-06-02 Jefferies Virtual Healthcare Conference Conference
2021-05-12 Minerva Neurosciences First Quarter 2021 Conference Call Earnings call
2021-03-08 Minerva Neurosciences Fourth Quarter 2020 Conference Call Earnings call
2020-11-17 Jefferies London Healthcare Conference Conference
2020-11-02 Minerva Neurosciences Third Quarter 2020 Conference Call Earnings call
2020-09-16 H. C. Wainwright 22nd Annual Global Investment Conference Conference
2020-09-09 Citi 15th Annual Biopharma Conference Conference
2020-08-19 JMP Securities CNS Forum Event
2020-08-03 Minerva Neurosciences Second Quarter 2020 Conference Call Earnings call
2020-06-05 Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia Event
2020-05-04 Minerva Neurosciences First Quarter 2020 Conference Call Earnings call

Source: https://www.minervaneurosciences.com/investors-media/

Key facts CIK 1598646 CUSIP 603380205 13F (30d) 2 filings 2 filers Visit website Investor relations